Livzon Pharma Reports No Change in Share Capital for August 2026

Bulletin Express
Sep 01

Livzon Pharmaceutical Group Inc. (Livzon Pharma) filed its Monthly Return for the period ended 31 August 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised Share Capital • H shares: 299.81 million shares at RMB 1 par value, amounting to RMB 299.81 million. • A shares: 588.10 million shares at RMB 1 par value, amounting to RMB 588.10 million. • Total authorised capital: 887.91 million shares, equivalent to RMB 887.91 million.

Issued Share Capital and Treasury Position • H shares in issue: 299.81 million; treasury shares: 0. • A shares in issue: 588.10 million; treasury shares: 0. • Total issued shares align with authorised figures, indicating no new issuance, cancellation or repurchase activity in August.

Public Float The company confirmed compliance with the Hong Kong Stock Exchange’s minimum 5 % public float requirement for its H-share class.

Corporate Actions The filing states that during the month there were: • No share options granted, exercised or lapsed. • No warrants, convertible securities, or other agreements that could dilute equity. • No Hong Kong Depositary Receipts outstanding or issued.

Administrative Details The return was submitted on 1 September 2026 by Company Secretary Liu Ning, with standard confirmations that all regulatory and listing requirements have been satisfied.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10